Related Experiment Videos
Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of
P Macchioni1, L Boiardi, R Meliconi
12 Divisione di Medicina Interna (Unità Reumatologica), Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
Objective:
To determine the levels of serum soluble intercellular adhesion molecule 1 (sICAM-1) in patients with polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA) prior and during steroid therapy.
Methods:
Sixteen patients with PMR and/or GCA had complete clinical and laboratory investigations at diagnosis before treatment and 9 patients were followed during 6 months of steroid therapy. Serum sICAM-1 levels were measured by ELISA:
Results:
Serum ICAM-1 levels were higher in the patient group compared to a control population. No significant correlation was found between serum sICAM-1 levels and other indices of disease activity. After steroid administration, a dramatic fall in serum sICAM-1 levels was observed at the end of the first week and persisted until the end of the study period, paralleling clinical and laboratory disease remission.
Conclusion:
Serum sICAM-1 levels paralleled disease activity in PMR and/or GCA. Steroid treatment induced a rapid normalization of the serum sICAM-1 levels.
Insights
Serum soluble intercellular adhesion molecule 1 (sICAM-1) levels were elevated in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) patients. Steroid therapy rapidly reduced sICAM-1, indicating its role in disease activity.
Area of Science:
- Rheumatology
- Immunology
- Biomarkers
Background:
- Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory conditions.
- Intercellular adhesion molecules play roles in inflammatory processes.
Purpose of the Study:
- To measure serum soluble intercellular adhesion molecule 1 (sICAM-1) levels in PMR and GCA patients.
- To assess the impact of steroid therapy on sICAM-1 levels.
Main Methods:
- Serum sICAM-1 levels were quantified using ELISA.
- Sixteen patients with PMR and/or GCA were studied before and during steroid treatment.
Main Results:
- Patients with PMR/GCA exhibited higher sICAM-1 levels than controls.
- A significant decrease in sICAM-1 was observed within the first week of steroid therapy.
- sICAM-1 levels correlated with disease activity and remission.
Conclusions:
- Serum sICAM-1 is a potential biomarker for disease activity in PMR and GCA.
- Steroid treatment effectively reduces sICAM-1 levels, mirroring clinical improvement.